SYFOVRE (Apellis Australia Pty Ltd)
Product name
SYFOVRE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
246 (255 working days)
Active ingredients
pegcetacoplan
Registration type
EOI
Indication
SYFOVRE is indicated for the treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth.
The benefits and risks of intravitreal pegcetacoplan should be discussed with the patient prior to commencing treatment. SYFOVRE should be administered by an eye specialist experienced in the management of geographic atrophy.